

Invariant Natural Killer T cell dynamics in HIV-associated tuberculosis

Naomi F. Walker^{1,2,3,4} PhD, Charles Opondo PhD⁵, Graeme Meintjes^{1,3} PhD, Nishta Jhilmee¹ PhD, Jon S Friedland⁶ FMedSci, Paul T Elkington^{2,7} FRCP, Robert J Wilkinson^{1,3,8,9} F Med Sci, Katalin A Wilkinson^{1,3,8} PhD.

¹Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of South Africa

²Infectious Diseases and Immunity, and Imperial College Wellcome Trust Centre for Global Health, Imperial College London, W12 0NN, United Kingdom

³Department of Medicine, University of Cape Town, Observatory 7925, Republic of South Africa

⁴TB Centre and Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, United Kingdom

⁵Department of Medical Statistics, London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, United Kingdom

⁶Institute of Infection & Immunity, St. George's, University of London, London, SW17 0RE, United Kingdom

⁷NIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, United Kingdom

⁸The Francis Crick Institute, London, NW1 1AT, United Kingdom

⁹Department of Medicine, Imperial College London, W2 1PG, United Kingdom

Address for correspondence:

Dr Katalin Wilkinson
The Francis Crick Institute
1 Midland Road, London NW1 1AT
Email: katalin.wilkinson@crick.ac.uk

Summary:

iNKT cells were depleted in patients with advanced HIV infection, most significantly immunoregulatory CD4+ subsets.

In patients with HIV-associated TB who developed TB-IRIS, iNKT cells were elevated with increased degranulation compared to non-IRIS patients, implicating iNKT cells in TB-IRIS immunopathology.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Rationale: Tuberculosis (TB) is the leading cause of mortality and morbidity in people living with HIV infection. HIV-infected patients with TB disease are at risk of the paradoxical TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) when they commence anti-retroviral therapy. However, the pathophysiology is incompletely understood and specific therapy is lacking.

Objectives: We investigated the hypothesis that invariant Natural Killer T (iNKT) cells contribute to innate immune dysfunction associated with TB-IRIS.

Methods: In a cross-sectional study of 101 HIV-infected and -uninfected South African patients with active TB and controls, iNKT cells were enumerated using α -galactosylceramide-loaded CD1d tetramers and subsequently functionally characterised by flow cytometry. In a second study of 49 HIV-1-infected TB patients commencing anti-retroviral therapy, iNKT cells in TB-IRIS patients with non-IRIS controls were compared longitudinally.

Measurements and main results: Circulating iNKT cells were reduced in HIV-1 infection, most significantly the CD4⁺ subset, which was inversely associated with HIV-1 viral load. iNKT cells in HIV-associated TB had increased surface CD107a expression, indicating cytotoxic degranulation. Relatively increased iNKT cell frequency in HIV-infected patients with active TB was associated with development of TB-IRIS following anti-retroviral therapy initiation. iNKT cells in TB-IRIS were CD4⁺CD8⁻ subset deplete and degranulated around the time of TB-IRIS onset.

Conclusions: Reduced iNKT cell CD4+ subsets as a result of HIV-1 infection may skew iNKT cell functionality towards cytotoxicity. Increased CD4- cytotoxic iNKT cells may contribute to immunopathology in TB-IRIS.

Key words: invariant Natural Killer T cell; HIV; tuberculosis; paradoxical immune reconstitution inflammatory syndrome (IRIS); innate.

Introduction

Tuberculosis (TB) causes 1.6 million deaths annually and is the leading cause of death in HIV-1 infected people (1). Anti-retroviral therapy (ART) naive HIV-1-infected patients with TB are at risk of the paradoxical TB immune reconstitution inflammatory syndrome (TB-IRIS) after commencing ART (2). Paradoxical TB-IRIS is characterised by an acute inflammatory response to *Mycobacterium tuberculosis* (Mtb) presenting as a clinical deterioration in a patient already receiving TB treatment, typically around two weeks post ART initiation (3). Paradoxical TB-IRIS is difficult to manage, frequently requiring non-specific immunosuppression with corticosteroids. Risk factors include disseminated TB and low CD4 T cell count at ART initiation, but the pathophysiology is incompletely defined (4). Recent studies have identified potential contributory innate immune mechanisms, including neutrophil recruitment, inflammasome activation and proinflammatory cytokine excess (5-10). These potential mechanisms have been recently reviewed (2)

Invariant natural killer T (iNKT) cells are a T cell subset that bridge innate and adaptive immunity, therefore are of interest in TB-IRIS pathogenesis (11). Distinct from NK cells and conventional T cells, iNKT cells express an invariant T cell receptor comprised of V α 24 and V β 11 in humans, and specifically recognise CD1d-presented lipid antigens, responding on activation with rapid cytokine production. Additionally, iNKT cells recognise and are potently activated by the marine sponge glycolipid α -galactosylceramide (α -galcer), bound to CD1d (12, 13).

Mtb cell wall is lipid-rich and therefore CD1d-presented molecules that activate iNKT cells may have a role in host immunity to Mtb (14, 15). *In vitro*, iNKT cells directly restricted Mtb growth and were bactericidal (16). In mice, augmenting iNKT cell responses with α -galcer

improved BCG vaccine efficacy and anti-tuberculosis treatment responses (17, 18). In non-human primates, increased iNKT cell frequency was associated with TB resistance (19). In humans, a limited number of studies have demonstrated numerical and functional defects of iNKT cells in active TB (20-23).

We previously reported elevated expression of cytotoxic mediators, perforin and granzyme B, in peripheral blood mononuclear cells (PBMC) in response to Mtb antigen stimulation and elevated frequencies of cytotoxic cells expressing CD3 and V α 24 T cell receptor in TB-IRIS patients compared to non-IRIS controls, suggesting that iNKT cells may play a role in TB-IRIS (24). Here, we systematically investigated iNKT cells in cross-sectional and longitudinal studies addressing the hypothesis that iNKT cell dysfunction contributes to TB-IRIS immunopathology. We describe for the first time iNKT cell aberration in HIV-associated TB disease and increased cytotoxic iNKT cells in TB-IRIS patients.

Methods

Full methods are provided in the online supplement.

Study Participants

The study was approved by the University of Cape Town Human Research Ethics Committee (REF 516/2011). All participants provided written informed consent. Cross-sectional study participants were retrospectively designated into four categories:

- 1) HIV-uninfected patients without active TB (HIV-TB-)
- 2) HIV-uninfected patients with a new diagnosis of active TB (HIV-TB+)
- 3) ART naïve, HIV-infected patients without active TB (HIV+TB-)
- 4) ART naïve, HIV-infected patients with a new diagnosis of active TB (HIV+TB+).

Longitudinal study participants were ART naïve HIV-1-infected patients with a CD4 count

<200 cells/ μ L and recently diagnosed TB. Longitudinal study visits occurred at TB diagnosis (TB0), ART initiation (ARV0), two (ARV2) and four (ARV4) weeks of ART and if new symptoms suggesting TB-IRIS occurred. TB-IRIS diagnosis was assigned retrospectively on expert case review, using consensus criteria (3).

iNKT cell enumeration and characterisation

PBMC were isolated over Ficoll and cryopreserved. Cells were rapidly thawed in warmed RPMI/10% FCS, before viability staining with Violet LIVE/DEAD[®] Fixable stain kit (VIVID, Invitrogen, Paisley, UK), then washed and re-suspended for incubation with either α -galcer-loaded CD1d tetramer or control CD1d tetramer (Proimmune, Oxford, UK) for 30 minutes on ice, protected from light. Subsequently, cells were washed, stained with antibody mastermix 1 (Supplementary Table S1) for 30 minutes at 4°C, washed and re-suspended in PBS, 1% Hi-FCS and 2% paraformaldehyde, then incubated for 1 hour, washed and resuspended for acquisition.

Data acquisition and analysis

Data were acquired on an LSRFortessa[™] (BD Biosciences, USA) and analysed using Flowjo software (Tree Star, Ashland, OR). iNKT cells were defined as CD3⁺ CD19⁻ CD1d α -galcer tet⁺ V β 11⁺ T cells. The gating strategy is shown in Figure 1A. iNKT cell frequency was calculated as a percentage of CD3⁺ CD19⁻ live lymphocytes, with subtraction of the equivalent tetramer negative control proportion, and reported per million CD3⁺CD19⁻ live lymphocytes. iNKT cell numbers were calculated by multiplying the iNKT cell frequency as a percentage of live lymphocytes with the total lymphocyte count per millilitre of peripheral blood (22).

Statistical analysis was performed using Prism 6 (GraphPad, UK) and STATA 14. Unadjusted non-parametric analyses were by two-tailed Fisher's Exact or Mann-Whitney U, or for comparisons of more than two groups, by Kruskal-Wallis with Dunn's multiple comparisons test. In the cross-sectional study, we used a multivariable linear regression model to investigate differences in iNKT cell frequency and in percentage iNKT cell CD4/CD8 expression by disease category. In the longitudinal study, a multivariable negative binomial model was fitted to examine associations of iNKT cell frequency and number with TB-IRIS status, and a multivariate linear regression model to estimate difference in CD4/CD8 cell subset percentages between TB IRIS and non-IRIS patients.

Results

PBMC samples were available from 101 patients (see Table 1). HIV+TB+ patients compared to HIV+TB- patients had lower total CD4 counts but similar CD4 percentages, and higher HIV-1 viral loads. In HIV+TB+ compared to HIV-TB+, there were trends towards reduced cavitary ($p=0.067$), but increased miliary ($p=0.051$) and extra-pulmonary ($p=0.054$) TB presentation, indicating reduced destructive pulmonary pathology but more widely disseminated TB disease in HIV-infected patients (25).

Circulating iNKT cells are depleted in HIV-1 infection and active TB

In an unadjusted analysis, comparing iNKT cell frequency in HIV-1-infected and -uninfected patients, with and without active TB, we found that iNKT cell frequency was reduced in HIV+TB+ ($p=0.001$) and HIV+TB- ($p=0.005$) compared to HIV-TB- patients (Figure 1B and Table 2). Example plots are shown in Supplementary Figure S1. A similar pattern was observed in comparison of iNKT cell numbers (iNKT cells per ml, Figure 1C) and reduction in iNKT cells numbers was found in HIV-TB+ compared to HIV-TB- patients ($p=0.044$).

Linear regression comparing HIV-TB+, HIV+TB- and HIV+TB+ to HIV-TB- provided further evidence of association between reduced iNKT cell frequency in HIV+TB- ($p=0.023$) and HIV+TB+ ($p=0.024$) after adjustment for age and sex, but there was no evidence of a reduction in iNKT cell frequency in HIV-TB+ compared to HIV-TB- ($p=0.301$).

CD4+ iNKT cell subsets are depleted in HIV-1 infection

iNKT cells may exist as CD4+CD8-, CD4-CD8+, CD8+CD4+, or double negative (DN) subsets. CD4+ iNKT cells secrete both Th1 and Th2 cytokines and may be immunoregulatory, whilst CD8+ iNKT cells and DN iNKT cell subsets predominantly secrete Th1 cytokines and have increased cytotoxic functionality (26, 27). Unadjusted analyses showed that HIV-1 infection was associated with lower CD4+ iNKT cell percentages (Figure 2A) and frequency (CD4+ iNKT cells per million CD3+ CD19- live lymphocytes, Figure 2B) in patients with ($p=0.007$) and without ($p=0.005$) active TB. Active TB did not clearly reduce CD4+ iNKT cell percentage, but was associated with reduced CD4+ iNKT cell frequency in HIV-uninfected patients (Figure 2B, $p=0.016$). In HIV-infected patients, total iNKT cell frequency did not correlate with peripheral blood CD4 T cell count, peripheral blood CD4 T cell percentage or HIV-1 viral load. However, CD4+ iNKT cell percentage was correlated with total peripheral blood CD4 T cell count (Figure 2C, $r=0.456$, $p=0.001$) and there was an inverse correlation with HIV-1 viral load (Figure 2D, $r=-0.571$, $p<0.001$), indicating most severe depletion of CD4+ iNKT cells occurred in advanced HIV infection.

Next, we examined CD4 and CD8 co-expression on iNKT cells. In HIV-TB-, we found CD4+CD8- (Figure 2E) and DN iNKT cells (Figure 2F) to be the predominant iNKT cell subsets constituting a median of 42.1% and 43.7% of the iNKT cell population respectively.

However, compared to HIV-TB- patients, HIV-infected patients had reduced percentages of CD4+CD8- iNKT cells, constituting a median of only 1.55% iNKT cells in HIV+TB+ ($p < 0.001$). In HIV-infected patients, there was a trend towards an increased percentage of CD4-CD8- iNKT cells (Figure 2F) and CD4-CD8+ iNKT cells (not shown), compared to HIV uninfected patients. To explore this further, we performed regression analysis comparing CD4/CD8 iNKT cell percentages in each group to HIV-TB-, adjusting for age and sex (Supplementary Table S2). This analysis showed evidence of reduced CD4+CD8- iNKT cells in HIV+TB- and HIV+TB+ compared to HIV-TB- ($p < 0.001$ for both) and increased CD4-CD8- percentage in HIV+TB- ($p = 0.010$). CD4-CD8+ cells were increased in HIV+TB- ($p = 0.037$) and HIV+TB+ ($p = 0.016$) compared to HIV-TB-. For CD4/CD8 subset iNKT cell frequencies, see Supplementary Figure S2.

iNKT cells in HIV-associated TB are pro-inflammatory with a cytotoxic phenotype

There was high iNKT cell surface expression of the maturation marker, CD161, CD95 and PD1 in HIV+TB+, but not more than in the control groups (data not shown). We investigated iNKT cell degranulation by measuring CD107a surface expression (28). CD107a+ iNKT cells were increased in HIV+TB+ patients, compared to HIV+TB- patients, suggesting increased cytotoxic degranulation (Figure 3A), but this phenotype was not observed in all HIV+TB+ patients. To explore this further, we investigated association between CD107a+ iNKT cell positivity and TB disease phenotype in HIV+TB+. We found significantly increased CD107a+ iNKT cell percentage in HIV+TB+ patients with clinical features of extrapulmonary TB compared to those without, consistent with the hypothesis that disseminated Mtb might lead to peripheral blood iNKT cell degranulation (Figure 3B).

In summary, we found that HIV infection was associated with iNKT cell depletion and CD4+ iNKT cell subsets were most significantly depleted in advanced HIV. Active TB was associated with a modest reduction in iNKT cell number in HIV-uninfected patients, but did not clearly reduce iNKT cell frequency. The immunoregulatory CD4+CD8- iNKT cell subset, the predominant subset in the healthy repertoire, was depleted in HIV-infected patients with and without active TB. CD4-CD8+ and DN iNKT cells were the dominant iNKT cell subsets in HIV-infected patients. There were increased CD107a+ iNKT cell percentages in HIV-infected patients with active TB, indicating a cytotoxic phenotype, which was associated with extra-pulmonary TB.

iNKT cell frequency is increased in TB-IRIS patients

Next, in a longitudinal study, we evaluated iNKT cells in patients with advanced HIV and recently diagnosed TB, who commenced TB treatment and then ART, and were at risk of paradoxical TB-IRIS. Fifty-seven participants were enrolled. Clinical features of this cohort have previously been reported (25). Paradoxical TB-IRIS was diagnosed in 29 (59.2%) patients. Participants were included if PBMC were available at least one study timepoint (TB0, ARV0, ARV2 and ARV4) and there was follow up to ARV12. One participant was excluded as no PBMC samples were available, another as they were an elite controller and therefore likely to be immunologically distinct, and a third due to hepatotoxicity on TB treatment resulting in a significant delay to ART initiation. The subsequent analysis reports findings from 29 TB-IRIS patients and 17 non-IRIS controls. Patient demographics and TB diagnosis are provided in Table 3 and were not significantly different comparing TB-IRIS with non-IRIS patients. Between ARV0 and ARV4, peripheral blood CD4 T cell counts increased ($p < 0.001$) from median 101 cells/ μl to 206 cells/ μl in TB-IRIS patients and from 99 cells/ μl to 175 cells/ μl in non-IRIS patients.

First, we enumerated iNKT cells. We found an elevated iNKT cell frequency in TB-IRIS compared to non-IRIS patients (Figure 4A). At ARV2, the most frequent time of TB-IRIS presentation, the median iNKT cell frequency per million CD3+CD19- live lymphocytes in TB-IRIS was 992 (IQR, 166-5682) compared to 100 (IQR 24.5-440) in non-IRIS patients ($p=0.025$ in unadjusted analysis). Multivariable modelling including data from timepoints ARV0, ARV2 and ARV4 demonstrated a significant association between TB-IRIS and increased iNKT cell frequency, adjusted for age and sex ($p=0.022$, Supplementary Table S3), but no increase in iNKT cell frequency over time and the association did not differ with total peripheral blood CD4 T cell count, nor HIV viral load. A similar trend was found for iNKT cell numbers in the adjusted logistic regression analysis ($p=0.062$, Supplementary Figure S3).

iNKT cell function and phenotype in TB-IRIS

Next, we examined CD4/CD8 iNKT cell subsets in the longitudinal study. CD4+ iNKT cell percentage and frequency were low, both in TB-IRIS and non-IRIS patients and did not increase in the first four weeks of ART, despite an increased peripheral blood CD4 T cell count. CD4+CD8- iNKT cell percentage was significantly lower in TB-IRIS patients than non-IRIS patients, ($p=0.015$ by multivariate linear regression modelling, Figure 4B and Supplementary Table S4). Supplementary Figure S4 shows CD4/CD8 subset frequency demonstrating a predominance of DN and CD4-CD8+ iNKT cells in TB-IRIS compared to non-IRIS patients, at ARV2 ($p=0.029$ and $p=0.036$ respectively).

In both TB-IRIS and non-IRIS patients, CD161+ iNKT cell and CD107a+ iNKT cell percentages were dynamic (Supplementary Figure 5 A-B). CD95 cell surface expression, indicative of cytotoxicity, and PD1+ iNKT cell percentages were high both in TB-IRIS and

non-IRIS patients whilst CD40L+ iNKT cell percentages were relatively low, possibly indicating iNKT cell exhaustion (Supplementary Figure S5 C-E) (22, 29). In TB-IRIS, CD161+ iNKT cell percentages decreased between ARV0 and ARV2, suggesting a loss of mature iNKT cells, whereas in non-IRIS patients, iNKT cell CD161 positivity was similar (Figure 5A). In TB-IRIS patients, CD107a+ iNKT cells increased between ARV0 and ARV2 relative to non-IRIS patients, suggesting degranulation occurred at the time of IRIS symptom onset (Figure 5B). CD107a+ iNKT cell frequency was increased in TB-IRIS compared to non-IRIS patients at ARV2 (Figure 5C).

In summary, patients with advanced HIV and active TB had low circulating iNKT cell frequency pre-ART initiation, but iNKT cell populations were skewed towards pro-inflammatory, cytotoxic subsets. Higher iNKT cell frequency was associated with TB-IRIS following ART initiation and iNKT cells in TB-IRIS patients were CD4+CD8- subset deplete, with increased DN and CD4-CD8+ iNKT cell frequency at the time of TB-IRIS onset. Increased CD107a+ iNKT cell subsets in TB-IRIS patients also at ARV2 suggested increased iNKT cell degranulation occurring at the time of TB-IRIS presentation.

Discussion

In this study, we demonstrated low iNKT cell frequency in ART-naïve patients with advanced HIV infection, with a paucity of CD4+ iNKT cells, and relatively increased proportions of CD4-CD8- iNKT cells, representing a shift from CD4+ subsets found in HIV-uninfected patients. Decreased iNKT cell numbers and CD4+ iNKT cell frequency were associated with active TB in patients without HIV infection, but this finding was not consistent in HIV-infected patients. In HIV-infected patients with active TB, increased degranulation of iNKT cells was found. Despite low iNKT cell frequencies in these patients,

there were relatively increased iNKT cells in patients who went on to develop TB-IRIS compared to those who did not and these were predominantly DN or CD4-CD8+ iNKT cells. There was no significant recovery in peripheral blood CD4+ iNKT cells in the first four weeks of ART, despite increased peripheral blood CD4 count (25).

Our findings are consistent with prior human studies measuring iNKT cells in HIV infection, which report reduced iNKT cell frequency in HIV-infected patients (23, 30, 31). A previous study demonstrated that *in vitro* HIV-1 infection directly infects and selectively depletes CD4+ iNKT cells. Activated iNKT cells were more susceptible to HIV-1 infection than conventional CD4 T cells. (32). In HIV-leprosy co-infection, iNKT cell populations were found to be reduced more profoundly than in leprosy or HIV infection alone (33). iNKT cell activation due to mycobacterial infection might exacerbate iNKT cell depletion in HIV-1 infected patients. Although we found the lowest iNKT cell frequency and numbers in patients with HIV-1 infection and active TB, active TB did not clearly have an additive effect of iNKT cell depletion in HIV-infected patients.

There are a number of potential mechanisms by which iNKT cells may contribute to immunopathology in TB-IRIS. They may directly recognise foreign or self lipid antigens presented via CD1d, or become activated by local cytokine networks (26). Once activated iNKT cells may rapidly secrete proinflammatory cytokines and chemokines promoting CD4 T cell expansion, activation and neutrophil infiltration, features of TB-IRIS we have previously shown, in addition to causing cell death (5, 6, 9, 10, 26, 34). Ultimately, this cascade may lead to MMP activation and tissue destruction, in turn propagating proinflammatory cytokine secretion in the vicious cycle of hyperinflammation that is the hallmark of TB-IRIS (7, 25).

iNKT cell quantification using α -galcer-loaded CD1d-loaded tetramers, is recognised as a stringent method of iNKT cell quantification (35, 36). However, we cannot extrapolate our findings beyond the limitations of this methodology, which may be affected by TCR downregulation on activation, nor beyond peripheral blood into tissue compartments (35). It is possible that increased circulating iNKT cells in TB-IRIS patients represents failure of migration to tissues. We found evidence of increased iNKT cell degranulation in extra-pulmonary TB, compared to pulmonary TB, raising the possibility that more abundant, disseminated Mtb antigen may drive iNKT cell degranulation in HIV-associated TB and increased iNKT cell cytotoxicity in TB-IRIS patients (24).

As a rare T cell subset, iNKT cells have formerly been difficult to study and iNKT cell function in infection is a relatively understudied area. However, in the field of oncology, adjuvants to boost iNKT cell cytotoxicity have been the focus of translational research and have entered early phase clinical trials (37, 38). Our study suggests that boosting iNKT cell cytotoxicity would not be an appropriate strategy in HIV-associated TB. However, an improved understanding of the role of iNKT cells in TB immunopathology could identify novel therapeutic targets. As human and mouse iNKT cell physiology differ, further human clinical and cellular studies are required, including study of iNKT cells in tissue compartments.

Conclusion

This study supports a role for iNKT cells in innate immune dysfunction in paradoxical TB-IRIS. We have shown profound CD4⁺ iNKT cell subset depletion in advanced HIV-1 infection and a lesser effect of active TB in HIV-uninfected patients. In patients with

advanced HIV and a new diagnosis of active TB, iNKT cell populations were skewed towards a proinflammatory, cytotoxic phenotype. Patients who developed TB-IRIS had increased iNKT cells compared to non-IRIS patients and iNKT cell degranulation occurred at the time of IRIS, potentially contributing to immunopathology.

Author Contributions

N.F.W., G.M., R.J.W., J.S.F., P.T.E. and K.A.W. conceived and designed the clinical study. N.F.W., G.M., and R.J.W. recruited the clinical cohort. N.F.W. N.J. R.J.W. and K.A.W. conceived and designed the cellular studies. N.F.W. and K.A.W. conducted the cellular studies. N.F.W and C.O. performed data analysis. N.F.W and K.A.W. hold all primary data and are responsible for the integrity of the data. All authors contributed to the writing of the manuscript and approved the final submitted version.

Acknowledgements

We thank S. Mansour for review of the draft manuscript.

Funding

NFW received funding from Wellcome (094000), The British Federation of Women Graduates (Elizabeth Bowden scholarship), and the Federation of African Immunological Societies and is currently supported by a National Institute for Health Research Academic Clinical Lecturership, the British Infection Association (Research Project Grant), and a Starter Grant for Clinical Lecturers (The Academy of Medical Sciences UK, Wellcome, Medical Research Council UK, British Heart Foundation, Arthritis Research UK, Royal College of Physicians and Diabetes UK); GM was supported by Wellcome (098316 and 203135/Z/16/Z), the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (Grant No 64787), NRF incentive funding (UID: 85858) and the South African Medical Research Council through its TB and HIV Collaborating Centres Programme with funds received from the National Department of Health (RFA# SAMRC-RFA-CC: TB/HIV/AIDS-01-2014); RJW and KAW receive support from the Francis Crick Institute which is supported by Wellcome

(FC001218), Medical Research Council (FC001218) and CRUK (FC001218), and the European Union Horizon 2020 research and innovation programme under grant agreement no. 643381; RJW receives additional support from Wellcome (104803, 203135), National Institutes of Health (U01AI115940), and European And Developing Countries Clinical Trials Partnership; NJ was supported by Wellcome (088316) and The South African National Research Foundation (443386).

Potential conflicts of interest

All authors: no reported conflicts of interest. All authors have submitted the ICMJE Uniform Disclosure Form for Potential Conflicts of Interest.

References

1. WHO. Global tuberculosis report 2018. World Health Organisation, Geneva, Switzerland, 2018.
2. Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G. The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. *Curr Opin HIV AIDS*. 2018;13(6):512-21.
3. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. *Lancet Infect Dis*. 2008;8(8):516-23.
4. Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, Meintjes G. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. *Future Microbiol*. 2015;10(6):1077-99.
5. Lai RP, Meintjes G, Wilkinson KA, Graham CM, Marais S, Van der Plas H, et al. HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. *Nature Commun*. 2015;6:8451.
6. Tadokera R, Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Seldon R, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. *Eur Respir J*. 2011;37(5):1248-59.
7. Tadokera R, Meintjes GA, Wilkinson KA, Skolimowska KH, Walker N, Friedland JS, et al. Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome. *Eur J Immunol*. 2014;44(1):127-36.
8. Andrade BB, Singh A, Narendran G, Schechter ME, Nayak K, Subramanian S, et al. Mycobacterial antigen driven activation of CD14⁺⁺CD16⁻ monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. *PLoS Pathog*. 2014;10(10):e1004433.

9. Marais S, Wilkinson KA, Lesosky M, Coussens AK, Deffur A, Pepper DJ, et al. Neutrophil-Associated Central Nervous System Inflammation in Tuberculous Meningitis Immune Reconstitution Inflammatory Syndrome. *Clin Infect Dis*. 2014;59(11):1638-47.
10. Nakiwala JK, Walker NF, Diedrich CR, Worodria W, Meintjes G, Wilkinson RJ, et al. Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome. *J Acquir Immune Defic Syndr*. 2018;77(2):221-9.
11. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. *Nat Immunol*. 2003;4(12):1164-5.
12. Kim CH, Johnston B, Butcher EC. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among Valpha 24(+)Vbeta 11(+) NKT cell subsets with distinct cytokine-producing capacity. *Blood*. 2002;100(1):11-6.
13. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. *Nat Immunol*. 2010;11(3):197-206.
14. De Libero G, Mori L. The T-Cell Response to Lipid Antigens of *Mycobacterium tuberculosis*. *Front Immunol*. 2014;5:219.
15. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. *Proc Natl Acad Sci U S A*. 2004;101(29):10685-90.
16. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells recognize *Mycobacterium tuberculosis*-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. *PLoS Pathog*. 2008;4(12):e1000239.
17. Venkataswamy MM, Baena A, Goldberg MF, Bricard G, Im JS, Chan J, et al. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of *Mycobacterium bovis* bacillus Calmette-Guerin. *J Immunol*. 2009;183(3):1644-56.

18. Sada-Ovalle I, Skold M, Tian T, Besra GS, Behar SM. Alpha-galactosylceramide as a therapeutic agent for pulmonary *Mycobacterium tuberculosis* infection. *Am J Respir Crit Care Med*. 2010;182(6):841-7.
19. Chancellor A, White A, Tocheva AS, Fenn JR, Dennis M, Tezera L, et al. Quantitative and qualitative iNKT repertoire associations with disease susceptibility and outcome in macaque tuberculosis infection. *Tuberculosis (Edinb)*. 2017;105:86-95.
20. Montoya CJ, Catano JC, Ramirez Z, Rugeles MT, Wilson SB, Landay AL. Invariant NKT cells from HIV-1 or *Mycobacterium tuberculosis*-infected patients express an activated phenotype. *Clin Immunol*. 2008;127(1):1-6.
21. Sutherland JS, Jeffries DJ, Donkor S, Walther B, Hill PC, Adetifa IMO, et al. High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting. *Tuberculosis*. 2009;89(6):398-404.
22. Kee SJ, Kwon YS, Park YW, Cho YN, Lee SJ, Kim TJ, et al. Dysfunction of Natural Killer T Cells in Patients with Active *Mycobacterium tuberculosis* Infection. *Infect Immun*. 2012;80(6):2100-8.
23. Paquin-Proulx D, Costa PR, Terrassani Silveira CG, Marmorato MP, Cerqueira NB, Sutton MS, et al. Latent *Mycobacterium tuberculosis* Infection Is Associated With a Higher Frequency of Mucosal-Associated Invariant T and Invariant Natural Killer T Cells. *Front Immunol*. 2018;9:1394.
24. Wilkinson KA, Walker NF, Meintjes G, Deffur A, Nicol MP, Skolimowska KH, et al. Cytotoxic mediators in paradoxical HIV-tuberculosis immune reconstitution inflammatory syndrome. *J Immunol*. 2015;194(4):1748-54.
25. Walker NF, Wilkinson KA, Meintjes G, Tezera LB, Goliath R, Peyper JM, et al. Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study. *Clin Infect Dis*. 2017;65(1):121-32.
26. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. *Nat Rev Immunol*. 2013;13(2):101-17.

27. Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. *PLoS Pathog.* 2009;5(4):e1000392.
28. Zeng SG, Ghnewa YG, O'Reilly VP, Lyons VG, Atzberger A, Hogan AE, et al. Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro. *J Immunol.* 2013;191(4):1666-76.
29. Liu TY, Uemura Y, Suzuki M, Narita Y, Hirata S, Ohyama H, et al. Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. *Eur J Immunol.* 2008;38(4):1012-23.
30. van der Vliet HJJ, von Blomberg BME, Hazenberg MD, Nishi N, Otto SA, van Benthem BH, et al. Selective Decrease in Circulating V α 24+V β 11+ NKT Cells During HIV Type 1 Infection. *J Immunol.* 2002;168(3):1490-5.
31. van der Vliet HJ, van Vonderen MG, Molling JW, Bontkes HJ, Reijm M, Reiss P, et al. Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. *J Immunol.* 2006;177(9):5775-8.
32. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human Natural Killer T cells are highly susceptible to human immunodeficiency virus 1 infection. *J Exp Med.* 2002;195(7):869-79.
33. Carvalho KI, Bruno FR, Snyder-Cappione JE, Maeda SM, Tomimori J, Xavier MB, et al. Lower numbers of Natural Killer T cells in HIV-1 and *Mycobacterium leprae* co-infected patients. *Immunology.* 2012;136(1):96-102.
34. Marais S, Lai RPJ, Wilkinson KA, Meintjes G, O'Garra A, Wilkinson RJ. Inflammasome Activation Underlying Central Nervous System Deterioration in HIV-Associated Tuberculosis. *J Infect Dis.* 2017;215(5):677-86.
35. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: Natural Killer T cell defects and human disease. *Nat Rev Immunol.* 2011;11(2):131-42.

36. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. *J Exp Med*. 1998;188(8):1521-8.
37. Nair S, Dhodapkar MV. Natural Killer T Cells in Cancer Immunotherapy. *Front Immunol*. 2017;8:1178.
38. Shissler SC, Bollino DR, Tiper IV, Bates JP, Derakhshandeh R, Webb TJ. Immunotherapeutic strategies targeting natural killer T cell responses in cancer. *Immunogenetics*. 2016;68(8):623-38.

Figure Legends

Figure 1 Reduced iNKT cells in HIV-1 infection and active TB

iNKT cells were enumerated by flow cytometry using α -galcer loaded CD1d tetramers. Each sample was stained in parallel with a control tetramer (without α -galcer) to identify non-specific tetramer binding for subtraction. The gating strategy shown in (A) demonstrates an iNKT cell frequency of 0.77%, with no control tetramer binding, equivalent to 7700 cells per million CD3⁺CD19⁻ live lymphocytes. Decreased iNKT cell frequency (B) was found in HIV-infected patients with active TB (HIV+TB⁺) and without active TB (HIV+TB⁻), compared to HIV-uninfected patients without active TB (HIV-TB⁻). Similarly, in HIV-infected patients with and without active TB, decreased iNKT cell numbers (cells per millilitre peripheral blood (C)) were found compared to HIV-uninfected patients without active TB. Additionally, in HIV-uninfected patients with active TB (HIV-TB⁺), iNKT cell numbers were reduced compared to HIV-uninfected patients without TB. Analysis was by Kruskal Wallis with Dunn's multiple comparison's test to calculate adjusted p values: *p<0.05; **p<0.01; ***p<0.001. In (B) and (C), zero values were replaced by one for representation on a log scale.

Figure 2 CD4⁺ iNKT cell subset depletion in HIV-1-associated TB

HIV-infected patients, most significantly those with active TB, had depleted CD4⁺ iNKT cells as measured by percentage of total iNKT cell count (A) and frequency per million CD3⁺CD19⁻ live lymphocytes (B). In HIV-infected patients, peripheral blood CD4 T cell count positively correlated with CD4⁺ iNKT cell percentage (C). HIV-1 viral load negatively correlated with CD4⁺ iNKT cell percentage (D). In HIV-uninfected patients without active TB, iNKT cells were mostly either CD4⁺ CD8⁻ or double negative (CD4⁻CD8⁻), whilst in HIV-infected patients CD4⁺ CD8⁻ iNKT cells were depleted and double negative iNKT cells

were the predominant subset (E, F). Analysis was by Kruskal Wallis with Dunn's multiple comparisons test to calculate multiplicity-adjusted p values: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ or by Spearman's correlation (C, D).

Figure 3 iNKT cell cytotoxicity in HIV-associated TB

In HIV-associated TB, there were increased percentages of CD107a+ iNKT cells, suggestive of cytotoxic degranulation (A). In HIV-infected patients with clinical features of extra-pulmonary TB (EPTB), there were increased CD107a+ iNKT cell percentages compared to HIV-infected patients with pulmonary TB (B). Analysis was by Kruskal Wallis with Dunn's multiple comparisons test to calculate multiplicity-adjusted p values or by Mann-Whitney U in (D): * $p < 0.05$.

Figure 4 iNKT cells are elevated in TB-IRIS patients and are CD4+CD8- subset deplete

iNKT cells were enumerated longitudinally by flow cytometry using α -galcer loaded CD1d tetramers, in a cohort of 46 HIV-1-infected patients with active TB. Samples were collected around the time of TB diagnosis (TB0), at anti-retroviral therapy initiation (ARV0, a median of 17.5 days post TB treatment initiation) and at two weeks (ARV2) and four weeks (ARV4) post-ART initiation although not all patients contributed data to the first timepoint as patients who had taken more than four doses of TB treatment at enrolment contributed data from ARV0, resulting in fewer data points at TB0. TB-IRIS presentation was typically at ARV2. Increased iNKT cell frequency (A) was observed in TB-IRIS patients compared to non-IRIS controls. CD4+CD8- iNKT cell percentages were reduced in TB-IRIS patients (B). Statistical analysis was by multivariable negative binomial modelling to examine associations of iNKT cell frequency and number with TB-IRIS status and by multivariate linear regression

modelling to estimate difference in CD4/CD8 cell subset percentages between TB IRIS and non-IRIS patients, including data from all timepoints to derive p values which are reported on the corresponding figure. In (A), zero values were replaced by one for representation on a log scale.

Figure 5 iNKT cell cytotoxicity associated with TB-IRIS

iNKT cells were characterised longitudinally by flow cytometric analysis for surface markers CD161 and CD107a, in TB-IRIS patients and non-IRIS patients. Between ARV0 and ARV2, CD161+ iNKT cells there was a reduction in CD161+ iNKT cell percentage in TB-IRIS compared to non-IRIS patients (A), whereas CD107a+ iNKT cell percentage increased in TB-IRIS patients between ARV0 and ARV2, compared to non-IRIS patients (B). CD107a+ iNKT cell frequency (cells per million CD3+CD19- live lymphocytes) was increased in TB-IRIS patients compared to non-IRIS controls at ARV2, the most common time of TB-IRIS presentation (C). Mann-Whitney U analysis for TB-IRIS vs non-IRIS: * $p < 0.05$; ** $p < 0.01$.

Table 1 Demographic and clinical features of the cross-sectional study participants

	<i>HIV-TB-</i>	<i>HIV-TB+</i>	<i>HIV+TB-</i>	<i>HIV+TB+</i>	<i>p value</i>
<i>n</i>	32	20	26	23	
<i>Female, n (%)</i>	14 (43.8)	7 (35.0)	15 (57.7)	9 (39.1)	>0.100 ^a
<i>Smoking status:</i> <i>current or ex., n (%)</i>	17 (53.1)	10 (50.0)	9 (34.6)	9 (39.1)	>0.100 ^a
<i>Age, median years (IQR)</i>	29.0 (23.3-38.8)	38.0 (30.0-42.8)	32.5 (28.5-35.3)	31.0 (28.0-40.0)	0.059 ^b
<i>CD4 T cell count,</i> <i>median cells/ml (IQR)</i>	N/A	N/A	349 (204-483)	187 (104-386)	0.041
<i>CD4 T cell percentage,</i> <i>median (IQR)</i>	N/A	N/A	17.8 (12.0-22.3)	13.7 (9.22-26.3)	0.901
<i>HIV viral load,</i> <i>median copies/ml (IQR)</i>	N/A	N/A	25735 (6807- 92169)	296196 (13540- 503097)	0.031
<i>Symptomatic, n (%)</i>	16 (50.0)	20 (100)	10 (38.5)	23 (100)	
<i>Duration of symptoms, median</i> <i>days (IQR)</i>	14.0 (4.00-150)	28.0 (14.0-30.0)	60.0 (11.3-82.5)	30.0 (21.0-30.5)	0.595 ^c
<i>Miliary TB, n (%)</i>	0 (0)	0 (0)	0 (0)	5 (21.7)	0.051 ^d
<i>Extrapulmonary TB, n (%)</i>	N/A	3 (15.0)	N/A	10 (43.5)	0.054 ^d
<i>Smear positive TB, n (%)</i>	0 (0)	13 (65.0)	0 (0)	8 (34.8)	0.069 ^d
<i>Culture positive TB, n (%)</i>	0 (0)	10 (50.0)	(0)	18 (78.3)	0.064 ^d
<i>Clinical diagnosis TB, n (%)</i>	0 (0)	3 (15.0)	0 (0)	2 (8.70)	0.650
<i>Cavitary disease on CXR,</i> <i>n (%)</i>	0 (0)	14 (70.0)	0 (0)	9 (39.1)	0.067 ^d

^afor comparison between each group by Fisher's Exact test

^bfor comparison of all groups by Kruskal-Wallis test, Dunn's multiple comparisons test for a difference between HIV-TB- and HIV-TB+ (p=0.033)

^cfor comparison of all groups by Kruskal-Wallis test

^dfor comparison between HIV-TB+ and HIV+TB+ by Fisher's Exact test

Table 2 iNKT cell enumeration in cross-sectional study participants by diagnosis

Patient category				Dunn's multiple comparisons test				
HIV- TB-	HIV- TB+	HIV+TB-	HIV+TB+	HIV- TB- vs. HIV- TB+	HIV- TB- vs. HIV+TB-	HIV- TB- vs. HIV+TB+	HIV+TB- vs. HIV+TB+	HIV- TB+ vs. HIV+TB+
<i>iNKT cell frequency, median per million CD3+CD19- live lymphocytes (IQR)</i>								
1700 (1125, 2600)	735 (253, 1800)	375 (198, 1775)	280 (62.7, 1300)	0.149	0.005	0.001	>0.999	0.731
<i>iNKT cell number, median cells per ml blood (IQR)</i>								
282628 (151100, 487870)	88580 (29600, 203771)	44965 (19635, 219669)	24439 (3789, 119449)	0.044	0.002	<0.001	0.432	0.161
<i>CD4+ iNKT cells, median percentage (IQR)</i>								
44.5 (27.9, 61.1)	38.9 (16.3, 67.1)	13.67 (2.77, 39.2)	3.15 (0, 39.6)	>0.999	0.005	<0.001	>0.999	0.007
<i>CD4+ iNKT cell frequency, median per million CD3+ CD19- live lymphocytes (IQR)</i>								
712 (451, 1043)	202 (78.8, 601)	100 (11.5, 236)	18.9 (0, 148)	0.016	<0.001	<0.001	>0.999	0.013

Table 3 Demographic and clinical features of participants in longitudinal study at enrolment

	<i>TB-IRIS</i>	<i>non-IRIS</i>	<i>p value</i>
<i>n (%)</i>	29 (63.0)	17 (37.0)	
<i>Female, n (%)</i>	14 (48.3)	10 (58.8)	0.552
<i>Smoking status: current or ex-, n (%)</i>	9 (31.0)	3 (17.5)	0.489
<i>Age, median years (IQR)</i>	35.0 (29.5-42.0)	35.0 (30.5-43.0)	0.924
<i>CD4 T cell count, median cells/μl</i>	89.0	82.0	0.987
<i>(IQR)</i>	(64.0-141.5)	(69.5-145.5)	
<i>HIV-1 viral load, median copies/ml</i>	621075	520295	0.343
<i>(IQR)</i>	(207018-1185455)	(126925-1029554)	
<i>Extrapulmonary TB, n (%)</i>	21 (72.4)	12 (70.6)	1.00
<i>Miliary TB, n (%)</i>	5 (17.2)	1 (5.88)	0.390
<i>Smear positive TB, n (%)</i>	14 (48.3)	5 (29.4)	0.235
<i>Culture positive TB, n (%)</i>	21 (72.4)	11 (64.7)	0.742
<i>Clinical diagnosis TB, n (%)</i>	2 (6.90)	4 (23.5)	0.174
<i>ART initiation, days post TB treatment initiation</i>	15	21	0.186
<i>(IQR)</i>	(14-28)	(14-41)	
<i>IRIS symptom onset, median days post-ART</i>	6	N/A	
<i>initiation (IQR)</i>	(4-10)		
<i>IRIS presentation, median days post-ART initiation</i>	14	N/A	
<i>(IQR)</i>	(9-15)		
<i>INSH^a criteria for paradoxical TB-IRIS fulfilled, n (%)</i>	25 (86.2)	0 (0)	

^aInternational Network for the Study of HIV-associated IRIS

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

